摘要
目的:研究miR-6861-5p在乳腺癌患者血清中的表达,并探讨miR-6861-5p表达在乳腺癌患者临床诊治中的价值。方法:通过实时荧光定量PCR法(RT-q PCR)检测2012年1月至2015年6月山东省德州市第二人民医院112例乳腺癌患者、37例乳腺良性病变和53例健康女性血清miR-6861-5p相对表达量,分析血清miR-6861-5p表达与乳腺癌患者临床病理和术后复发之间的关系,并探讨其表达对乳腺癌的临床诊断价值。结果:乳腺癌患者血清miR-6861-5p相对表达量为(7.99±1.63),显著高于良性病变患者(6.45±1.06)(P<0.05)和健康研究对象(6.43±1.28)(P<0.05);血清miR-6861-5p表达与乳腺癌患者淋巴结转移、肿瘤组织ER、PR和HER-2表达、TNM分期、分子分型以及组织学分期显著相关(均P<0.05);肿瘤切除后乳腺癌患者血清miR-6861-5p表达量显著降低;治疗前血清miR-6861-5p诊断乳腺癌的敏感度和特异度分别为69.6%和77.8%,且与乳腺癌患者术后复发率有关。结论:miR-6861-5p在乳腺癌患者血清中表达上调,是术前乳腺癌诊断、肿瘤分期、癌细胞转移和术后监测乳腺癌复发的潜在生物标志物。
Objective： This study was conducted to detect circulating miR-6861-5p and evaluate its diagnositic value in the diagnosis and treatment of breast cancer. Methods： Mi R-6861-5p expression was detected by RT-q PCR in 112 patients with breast cancer enrolled in the Second People Hospital of Dezhou from January 2012 to June 2015, with 37 patients diagnosed with benign breast lesions, and 53 healthy people. The relationship between circulating miR-6861-5p and clinicopathologic features and the postoperative recurrence of breast cancer was analyzed to explore the diagnostic value of circulating miR-6861-5p in patients with breast cancer. Results： Circulating miR-6861-5p expression was significantly higher in patients with breast cancer（7.99±1.63） than in patients with benign breast lesions（6.45±1.06） and healthy people（6.43±1.28）（P〈0.05）. There was a significant correlation between circulating miR-6861-5p and lymph node metastasis, estrogen receptor, progesterone receptor, HER-2 expression, TNM staging, molecular typing, and histological staging in patients with breast cancer（P〈0.05）. Circulating miR-6861-5p significantly decreased after tumor resection（P〈0.05） and was significantly correlated with the recurrence rates after treatment. The sensitivity and specificity of diagnosis in breast cancer by detecting circulating miR-6861-5p were 69.6% and 77.8%, respectively. Conclusions： There is high expression of circulating miR-6861-5p in breast cancer, which may serve as useful diagnostic, staging, cancer cell metastasis, and postoperative recurrence biomarker in patients with breast cancer.
作者
袁超
Chao Yuan(Department of Breast Diseases, The Second People Hospital of Dezhou, Dezhou 253004, Chin)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2018年第5期241-245,共5页
Chinese Journal of Clinical Oncology
